Classifieds - Imaging in Oncology

Article

      Taking place in London this year, SMi’s Imaging in Oncology will focus on a wide range of imaging techniques in a wide range of settings - from the preclinical, to the clinical, to the future of oncological imaging. 

Imaging in Oncology10th and 11th March 2010, Crowne Plaza St James Hotel, London

Sponsored by:Bioclinica, Bracco, Caliper Lifesciences, Perceptive Informatics and Rad Pharm  

For more information visit us at: www.smi-online.co.uk/2010oncology24.asp

     
Taking place in London this year, SMi’s Imaging in Oncology will focus on a wide range of imaging techniques in a wide range of settings - from the preclinical, to the clinical, to the future of oncological imaging.
 

Attend this event to

• Hear from the leading lights of the imaging world about their latest research into imaging technique

• See imaging techniques you know being used for procedures you do not know

• Learn where the future lies for imaging in oncology

• Network with the people you need to know in the imaging arena
 

>>>

PLUS

a pre conference workshop in association with

3D Metrics

<<<


Differentiating Cell Types as a Precondition for Diagnosing and Treating Cancer


Hosted by Sabine McNeill, Director,3D-Metrics
9th March 2010, Crowne Plaza Hotel – St James, London
This workshop will cover an innovative approach to image analysis, which allows for comparing images as a whole as well as regions of interest.   This means that hundreds and thousands of images can be compared at 'pixel resolution', which means at more detail and with more accuracy than the imaging technology currently used.  Existing images are 're-visualised' on an individual basis for the human eye.  Development is taking place so that hundreds and thousands of images can be 'viewed' by the software in an automated fashion.  However, this requires input from the image analysts who are familiar with what they are looking for. 
HOW TO BOOK
To book please visit: www.smi-online.co.uk/2010oncology24.asp
Alternatively, Contact Daniel Davies tel: +44 (0) 20 7827 6060 or email: ddavies@smi-online.co.uk

Download PDF

 

Recent Videos
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Related Content